Headspace Health Announces Acquisition of AI-Driven Mental Health and Wellness Company, Sayana
Headspace Health, the provider of the world’s most accessible, comprehensive digital mental health platform, today announced the acquisition of Sayana, an AI-driven mental health and wellness company. Sayana will expand Headspace Health’s ability to provide personalized self-care content to its growing global member base.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220112005244/en/
Headspace Health announces acquisition of AI-driven mental health and wellness company, Sayana.
Founded in 2018 and backed by Y Combinator in 2020, Sayana has supported users around the world to improve their mental wellness by helping its members become more mindful of the connections between their feelings and events. The Sayana Self-Care app leverages chat-based sessions with an AI persona named Sayana, who encourages users to track their mood along with what influences it. Sayana personalizes users’ experiences based on their check-ins and mood trends, surfacing high-quality content and self-care exercises rooted in cognitive behavioral therapy (CBT), acceptance commitment therapy (ACT) and dialectical behavioral therapy (DBT), as well as breathing exercises. In addition, the Sayana Sleep app helps members to enjoy deep and restful sleep sessions sequenced based on their mood and sleep patterns.
“Amidst a rapidly growing landscape of mental health and wellness apps, Sayana has developed a uniquely engaging member experience backed by world-class AI and machine learning algorithms,” said Russell Glass, CEO, Headspace Health. “Sayana's technology, and most importantly, Sayana’s team, will help us meaningfully advance our product and content strategy as we continue to build the world’s most comprehensive mental health and wellbeing platform.”
On the heels of its recent merger between Headspace and Ginger, Headspace Health is creating an integrated experience to tackle the full spectrum of mental health needs - from prevention to clinical care - all from one platform backed by AI and data science. Today, Ginger leverages AI to support its team of behavioral health coaches, therapists and psychiatrists to ensure quality interactions with members, comprehensive tracking of services, and close collaboration among care providers. Headspace harnesses the power of AI to surface and recommend content in order to foster healthy habit formation. With the addition of Sayana, Headspace Health will advance its capability to personalize member experiences - to better understand, support and improve their feelings and mood.
Sayana founder and CEO Sergey Fayfer will join Headspace Health and take on a product leadership role, along with an experienced team of engineers and designers who will further advance the company’s unique and engaging member experiences.
“Since our inception, we’ve been on a mission at Sayana to put self-care in everyone’s pocket,” said Sergey Fayfer, Founder and CEO of Sayana. “We’re thrilled to bring together our technology, engineering and design expertise to help advance Headspace Health’s efforts to democratize high-quality, affordable mental healthcare around the world.”
The terms of the deal were not disclosed.
About Headspace Health
Headspace Health is the world’s leading provider of mental health and wellbeing solutions. Through our flagship Headspace brand, we’ve touched the lives of over 100 million people in 190 countries through mindfulness tools for managing stress, sleep, and focus. Our enterprise brands, Headspace for Work and Ginger, are distributed through over 3,500 enterprises, including Starbucks, Adobe, Delta Air Lines, and ViacomCBS; and through health plans such as Cigna. Our members and enterprise partners’ employees have access to mindfulness and meditation tools, CBT, coaching, therapy, and psychiatry, ultimately helping them to be healthier and more productive. To learn more about Headspace Health and our family of brands, visit www.headspacehealth.com.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220112005244/en/
Contact information
Victoria Barnes
Sr. Director, Global Communications & Corporate Marketing, Headspace Health
781 249 3738
press@headspacehealth.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Brenus Pharma Reports Favorable Tolerability and Clinical Signals in Early Preliminary Results of First-In-Human Study for STC-1010 in Unresectable Metastatic Stage Colorectal Cancer (MSS CRC) Patients6.1.2026 22:00:00 EET | Press release
Brenus Pharma, a clinical stage biotechnology company unlocking the immune system in vivo to fight solid tumors, announced the successful completion of the first dose levels in its ongoing first-in-human study. The multi-center, open-label trial (NCT06934538) is a phase Ia/Ib study designed to evaluate safety, tolerability and preliminary clinical activity of STC-10101 in a first line setting. It will include in vivo analysis of immune and tumor dynamics during dose escalation of treatment and cohort extension to patients with unresectable locally advanced (stage IIIC, T4b) or unresectable metastatic (stage IV) MSS2 colorectal cancer (CRC). Early findings indicate that the first dose levels have been successfully completed with good overall tolerance and no-dose-limiting toxicities observed to date. “We are pleased to report that the safety profile observed to date is good and consistent with our expectations with no DLT,” said Paul Bravetti, CEO of Brenus Pharma. “Moreover, preliminar
SPIE, the International Society for Optics and Photonics, Announces Its 2026 Fellows6.1.2026 21:35:00 EET | Press release
SPIE, the international society for optics and photonics, welcomes 40 Members as new Fellows of the Society in the 2026 cohort. They join their Fellow Member colleagues in being honored for their excellent technical achievements, as well as for their substantial service to the optics and photonics community and to SPIE. Fellows are Members of the Society who have made significant scientific and technical contributions in the multidisciplinary fields of optics, photonics, and imaging. Since the Society's inception in 1955, more than 1,800 SPIE Members have become Fellows. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260106630672/en/ SPIE, the international society for optics and photonics, announces its 2026 Fellows This year’s inductees are high-profile leaders in academia, industry, and government, many of whom are particularly prominent in their support of the optics and photonics community and mentorship of others. “It’
Chemelex Adds Electric Heat Trace Group Ltd.’s SmartTrace Monitoring Platform to its Heat Tracing Portfolio6.1.2026 21:00:00 EET | Press release
Chemelex, a global leader in electric thermal and sensing solutions, today announced the successful completion of its acquisition of substantially all the assets and ongoing operations of Electric Heat Trace Group Ltd. (EHT Group), headquartered in Ontario, Canada. This strategic move marks an exciting start to the new year and reinforces Chemelex’s commitment to delivering smarter, data-driven solutions for industrial heat trace systems. EHT Group is a recognized innovator in heat trace management, offering advanced software, integrated controller solutions, wireless communication modules, and comprehensive field services. Its flagship platform, SmartTrace, is a robust solution available in both cloud-based and on-premises deployments that enables predictive maintenance, minimizes downtime, and provides secure remote monitoring—helping customers achieve greater reliability and operational efficiency. This endeavor will help Chemelex support greater operational efficiencies for our cus
ZIIHERA Plus TEVIMBRA and Chemotherapy: A Potential New Standard for First-Line HER2+ Advanced GEA6.1.2026 20:30:00 EET | Press release
BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced full results from the Phase 3 HERIZON-GEA-01 trial evaluating ZIIHERA® (zanidatamab), a HER2-targeted bispecific antibody, in combination with chemotherapy, with and without PD-1 inhibitor TEVIMBRA® (tislelizumab), as a first-line treatment for HER2-positive (HER2+) locally advanced or metastatic gastroesophageal adenocarcinoma (GEA). These data, including the first interim overall survival (OS) analysis, will be presented as a Late-Breaking Abstract Oral Presentation (#LBA285) at the American Society of Clinical Oncology Gastrointestinal Cancers Symposium (ASCO GI) on January 8, 2026, from 8:57- 9:07 a.m. PST. HERIZON-GEA-01 met the dual primary endpoint of progression-free survival (PFS), demonstrating statistically significant and clinically meaningful improvements in both experimental arms compared to the control arm. The addition of TEVIMBRA to ZIIHERA and chemotherapy also sho
Siemens and NVIDIA Expand Partnership to Build the Industrial AI Operating System6.1.2026 19:07:00 EET | Press release
CES 2026 - Siemens and NVIDIA today announced a significant expansion of their strategic partnership to bring artificial intelligence into the real world. Together, the companies aim to develop industrial and physical AI solutions that will bring AI-driven innovation to every industry and industrial workflow, as well as accelerate each others’ operations. To support development, NVIDIA will provide AI infrastructure, simulation libraries, models, frameworks and blueprints, while Siemens will commit hundreds of industrial AI experts and leading hardware and software. “Together, we are building the Industrial AI operating system – redefining how the physical world is designed, built, and run - to scale AI and create real-world impact,” said Roland Busch, President and CEO of Siemens AG. “By combining NVIDIA’s leadership in accelerated computing and AI platforms with Siemens’ leading hardware, software, industrial AI and data, we’re empowering customers to develop products faster with the
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
